Identification and antimicrobial susceptibility profiles of *Nocardi*a species clinically isolated in Japan

Masahiro Toyokawa1,2,4*, Noboru Ohana2, Akiko Ueda3, Minako Imai4, Daiki Tanno2,4, Mutsuko Honda4, Yukiko Takano4, Kazutaka Ohashi4, Kyoichi Saito2 & Hiroki Shimura2,4

The aims of the present study were to profile the antimicrobial susceptibility patterns of a diverse range of *Nocardi*a species isolated in Japan, and to determine the ability of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for species/complex identification. Identification of 153 clinical isolates was performed by full-length 16S rRNA gene sequencing as a reference method to evaluate the usefulness of MALDI-TOF MS identification. Antimicrobial susceptibility testing (AST) for 14 antibiotics was performed using the broth microdilution method against 146 of the isolates. Among the total 153 clinical isolates, *Nocardi*a farcinica complex (25%) was the most common species, followed by *Nocardi*a cyriacigeorgica (18%), *Nocardi*a brasiliensis (9%), *Nocardi*a nova (8%), and *Nocardi*a otitidiscaviarum (7%). Among 150 isolates identified to the species/complex level by 16S rRNA gene sequencing, MALDI-TOF MS with the use of a supplemental *Nocardi*a library (JMLD library ver.ML01) correctly identified 97.3% (n = 146) to the species/complex level and 1.3% (n = 2) to the genus level. Among the 146 *Nocardi*a isolates that underwent AST, the susceptibilities were 100% to linezolid, 96% to amikacin, 96% to trimethoprim-sulfamethoxazole, and 76% to imipenem. None of the trimethoprim-sulfamethoxazole-resistant isolates carried either plasmid-mediated sulfonamide-resistant genes (*sul1*, *sul2*) or trimethoprim-resistant genes (*dfrA*).

*Nocardi*a species are ubiquitous environmental organisms that can cause local or disseminated infection in humans. The lung is the most common primary site of infection, and central nervous system infection is often encountered through hematogenous dissemination from a pulmonary focus, particularly in immunocompromised hosts1. Prompt diagnosis and appropriate treatment of nocardiosis are required, because it is a fatal infection2. Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line agent for initial therapy for nocardiosis3, thus accurate determination of the susceptibility to TMP-SMX in clinical isolates is crucial. Conville et al. reported that the standard broth microdilution method for TMP-SMX may cause false resistance because of difficulties in end-point interpretation, and they recommend performing a confirmation test via sulfisoxazole disk diffusion testing4. Unfortunately we are unable to purchase sulfisoxazole disks in Japan; therefore there is no reliable data concerning *Nocardi*a isolates resistant to TMP-SMX in Japan. On the other hands, identification of clinical isolates to the species/complex level is important, because *Nocardi*a species differ in clinical spectrum and susceptibility patterns5–7. Gene sequencing such as 16S rRNA gene is currently used for the identification of *Nocardi*a species; however, recently, matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)-based identification has been identified as a rapid, easy and reliable method8,9.

The aims of the present study were to profile the antimicrobial susceptibility patterns of a diverse range of *Nocardi*a species isolated from clinical specimens in Japan, and to determine the utility of MALDI-TOF MS for the routine identification of *Nocardi*a species.

Materials and methods

**Bacterial isolates and identification.** A total of 153 clinical isolates of *Nocardi*a species recovered from patients in 25 microbiology laboratories in Japan were studied. The isolates were cultured from respiratory tract specimens (n = 90), skin and soft tissue (n = 14), blood (n = 5), deep abscess (n = 6), pleural effusion (n = 1), ascitic...
fluid (n = 1), synovial fluid (n = 1), others (n = 5) and unknown (n = 30). Identification of Nocardia species was based on Gram stain, colonial morphology and molecular technique. All isolates were identified by full-length 16S rRNA gene sequencing, for which the universal primers 5′-AGAGTTTGATCMTGCGCTGAC-3′ and 1495B (5′-ACGGGCGCTGGTRC-3′) were used, as described previously. We performed sequence analysis using a GenBank BLAST search and EzBioCloud (https://www.ezbiocloud.net/identify/result?id=5e99c3c39ad461904efaa33). Previously established criteria for identification of Nocardia isolates to the species or complex level were followed.

**MALDI-TOF MS identification.** All Nocardia species isolates were analyzed using a Microflex LT bench top mass spectrometer (Bruker Daltonics, Germany). MALDI Biotyper 3.1 software (Bruker Daltonics, MALDI Biotyper reference library version 8.0.0.0) was applied with the use of a supplemental Nocardia library (JMLD library ver.ML01, containing 114 Main Spectras for 46 Nocardia species) provided by BCKK MALDINOMICS (Beckman Coulter Japan, Tokyo, Japan). The isolates were cultivated on 5% sheep blood agar plates at 35°C, and tested at 18 and 48 h, an early stage of growth. Samples were prepared as previously described (on-plate extraction). Protein extraction was also performed using the formic acid/ethanol method according to the Bruker Daltonics’ protocol for any isolate failed to be identified by on-plate extraction. A spectral score of ≥ 2.00 was considered identification to the species level, a score of 1.700–1.999 indicated identification at the genus level, and a score of < 1.70 was considered unreliable identification.

Complex level identification was performed on some Nocardia species according to Conville’s criteria. Nocardia asteroides ATCC 23206, Nocardia brasiliensis ATCC 23238, Nocardia farcinica ATCC 23157, and Nocardia otitidiscaviarum ATCC 23240 were used as the quality control strains.

**Antimicrobial susceptibility testing (AST).** AST was performed using the broth microdilution method with frozen panels (Eiken Chemical, Tokyo, Japan), according to the Clinical and Laboratory Standards Institute (CLSI) M24-A2 guidelines against 146 clinical isolates. In brief, a heavy organism suspension was prepared in a small volume of sterile saline with 7–10 3-mm glass beads and was vortexed vigorously. Clumps were allowed to settle for 15 min, and the supernatant was adjusted to a 0.5 McFarland standard using a calibrated nephelometer. For frozen panel inoculation, the adjusted 0.5 McFarland suspension was diluted 30-fold with sterile saline and 10 µl of the diluted solution was dispensed into each well of the panel. The panels were incubated at 35°C for 72 h until moderate growth was observed in the growth control wells. For TMP-SMX, the MICs were determined as the wells corresponding to 80% inhibition of growth compared to the controls. The MICs were determined for TMP-SMX, amikacin, tobramycin, ceftriaxone, imipenem, minocycline, linezolid, ciprofloxacin, moxifloxacin, clarithromycin, cefotaxime (100 isolates only), meropenem (100 isolates only), tigecycline (100 isolates only), and arbekacin (100 isolates only), and interpreted as recommended by CLSI.

Identification of clinical isolates by full-length 16S rRNA gene sequencing. Among the 153 clinical isolates, 150 were identified to the species/complex level, including 24 different species/complexes, and the remaining three isolates were identified to the genus level (Table 1). Nocardia farcinica complex (n = 39; 25%) was the most common species, followed by Nocardia cyriacigeorgica (n = 27; 18%), Nocardia brasiliensis (n = 14; 9%), Nocardia nova (n = 12; 8%), Nocardia otitidiscaviarum (n = 11; 7%), Nocardia elegans (n = 10; 7%), Nocardia beijingensis (n = 7; 5%), N. nova complex (n = 4), Nocardia abscessus (n = 4), Nocardia asiatica (n = 4), Nocardia wallacei (n = 3), Nocardia sp. (n = 3), Nocardia transvalensis complex (n = 3), N. abscessus complex (n = 2), Nocardia thailandica (n = 2), and one each of Nocardia bovis, Nocardia asteroides, Nocardia takedensis, Nocardia pseudobrasiliensis, Nocardia yamashihimensis, Nocardia mexicana, and Nocardia vinacea.

N. cyriacigeorgica was the most frequently isolated Nocardia species from the respiratory tract (28%; 25/90), followed by N. farcinica complex (21%; 19/90). N. brasiliensis was isolated in one-half (50%; 7/14) of the skin and soft tissue samples. Figure 1 shows the alignment of 1405 bases of the 16S rRNA gene of all clinical isolates of Nocardia with those of closely related species obtained using the neighbor-joining method with MEGA X software.
Table 1. Comparison of full-length 16SrRNA gene sequencing and MALDI-TOF MS identification for 153 Nocardia spp. isolates using the manufacturer's library combined with a custom library. *2/3 isolates were identified as N. testacea/N. sienata, and 1/3 isolates was identified as N. testacea/N. sienata/N. rhhamnosiphila. †Two isolates were identified as N. araensis with scores of 1.91 and 1.99, respectively. ‡misidentified as N. brasiliensis with a score of 2.033.

MALDI-TOF MS identification. Among the 150 isolates that had identified to the species/complex level by 16S rRNA gene sequencing, MALDI-TOF MS correctly identified 97.3% (146/150) to the species/complex level and 1.3% (2/150) to the genus level (Table 1). One isolate, which was identified as N. transvalensis complex by 16S rRNA gene sequencing, was misidentified as N. brasiliensis, with a score ≥ 2.00. In addition, there was one isolate that could not be identified, with a score < 1.70. All three isolates identified to the genus level by 16S rRNA gene sequencing were identified as Nocardia species/complexes at a cutoff score level of:

- ≥ 2.0
- ≥ 1.7
- < 1.7 (no identification)

No. of isolates identified by MALDI-TOF MS at a cutoff score level of:

| Nocardia species/complex | MALDI-TOF MS identification | ≥ 2.0 | ≥ 1.7 | < 1.7 (no identification) | No. of isolated misidentification |
|--------------------------|-----------------------------|-------|-------|--------------------------|----------------------------------|
| N. farcinica complex (n = 39) | N. farcinica complex | 39    | 0     | 0                         | 0                                |
| N. cyaicigeorgica (n = 27) | N. cyaicigeorgica complex | 27    | 0     | 0                         | 0                                |
| N. brasiliensis (n = 14) | N. brasiliensis | 14    | 0     | 0                         | 0                                |
| N. otitidiscaviarum (n = 11) | N. otitidiscaviarum complex | 11    | 0     | 0                         | 0                                |
| N. novae (n = 12) | N. novae complex | 12    | 0     | 0                         | 0                                |
| N. elegans (n = 10) | N. elegans | 10    | 0     | 0                         | 0                                |
| N. aobensis (n = 1) | N. aobensis | 1     | 0     | 0                         | 0                                |
| N. novae complex (n = 4) | N. novae | 4     | 0     | 0                         | 0                                |
| N. abscessus (n = 4) | N. abscessus complex | 4     | 0     | 0                         | 0                                |
| N. asiatica (n = 4) | N. asiatica | 4     | 0     | 0                         | 0                                |
| N. beijingensis (n = 1) | N. beijingensis | 1     | 0     | 0                         | 0                                |
| N. abcessus complex (n = 2) | N. abcessus complex | 1     | 0     | 1                         | 0                                |
| N. wallacei (n = 1) | N. wallacei | 3     | 0     | 0                         | 0                                |
| N. transvalensis complex (n = 3) | N. transvalensis complex | 2     | 0     | 0                         | 1†                                |
| N. thailandica (n = 2) | N. thailandica | 2     | 0     | 0                         | 0                                |
| N. asteroides (n = 1) | N. asteroides | 1     | 0     | 0                         | 0                                |
| N. takedensis (n = 1) | N. takedensis | 1     | 0     | 0                         | 0                                |
| N. pseudobrasiliensis (n = 1) | N. pseudobrasiliensis | 1     | 0     | 0                         | 0                                |
| N. yumanashiensis (n = 1) | N. yumanashiensis | 1     | 0     | 0                         | 0                                |
| N. mexicana (n = 1) | N. mexicana | 1     | 0     | 0                         | 0                                |
| N. vinacea (n = 1) | N. vinacea | 1     | 0     | 0                         | 0                                |
| All 150 isolates (%) | 146 (97.3) | 2 (1.3) | 1 (0.7) | 1 (0.7) | 0                                |
| Nocardia sp. (n = 3) | N. testacea | 3     | 0     | 0                         | 0                                |

Antimicrobial susceptibility testing. The MIC range, MIC50, MIC90 and susceptibility for the seven most frequently isolated Nocardia species/complexes are shown in Table 2. The antibiograms of the uncommon Nocardia species are listed in Table 3.

Overall, linezolid was the most active drug across all species, with no in vitro resistance. Among the 146 Nocardia isolates that underwent AST, 96% were susceptible to amikacin; 86% were susceptible to TMP-SMX; and 76% were susceptible to imipenem. In contrast, about 80% of the Nocardia species/complexes were susceptible to clarithromycin, minocycline or ciprofloxacin. Six amikacin-resistant isolates were identified as N. transvalensis complex. The results of disk diffusion testing with a 250-μg sulfisoxazole disk and re-analysis of the broth microdilution method against 21 TMP-SMX-resistant isolates are shown in Table 4. Of these 21 isolates, five were interpreted as being TMP-SMX-resistant, and 12 were susceptible, while four were not interpretable. Finally, 94% (137/146) of the Nocardia isolates were determined to be susceptible to TMP-SMX. The isolates that were not susceptible to TMP-SMX (including isolates not interpretable) were found among N. otitidiscaviarum (27%; 3/11), N. farcinica complex (8%; 3/37), N. cyaicigeorgica (4%; 1/27), N. thailandica (1/2) and N. mexicana (1/1).
Figure 1. 16S rRNA sequence-based phylogenetic tree of clinical isolates of *Nocardia* with those of closely related species. The evolutionary history was inferred using the Neighbor-Joining method. The optimal tree is shown. The tree is drawn to scale, with branch lengths in the same units as the evolutionary distances used to infer the phylogenetic tree. Evolutionary analyses were conducted in MEGA X. The read length of N75 strain was 1023 bp with a good quality sequence.
| Bacterium (no of isolates tested) and antimicrobial agent | MIC (μg/ml) | Susceptibility (%)<sup>a</sup> |
|----------------------------------------------------------|-------------|-----------------------------|
| **Range**       | 50% | 90% | S | I | R |
| **N. farcinica complex** (37) |
| Amikacin | 0.06–4 | 1 | 2 | 37 (100) | 0 (0) | 0 (0) |
| Tobramycin | ≤0.015–0.064 | 32 | 64 | 1 (3) | 1 (3) | 35 (94) |
| Arbekacin (26) | 0.03–2 | 0.5 | 1 | – | – | – |
| Trimethoprim-sulfamethoxazole | 0.25/0.75–4/7.5 | 2/38 | 4/76 | 24 (65) | – | 13 (35) |
| Ceftriaxone | 1–2 | 64 | 256 | 1 (3) | 10 (27) | 26 (70) |
| Cefotaxime (26) | 0.125–0.25 | 64 | >256 | 1 (4) | 4 (15) | 21 (81) |
| Imipenem | 0.5–8 | 4 | 256 (95) | 2 (5) | 0 (0) |
| Meropenem (26) | 0.25–16 | 4 | 16 | – | – | – |
| Linezolid | 0.5–4 | 4 | 4 | 37 (100) | 0 (0) | 0 (0) |
| Ciprofloxacin | 0.25–16 | 2 | 8 | 17 (46) | 4 (11) | 16 (43) |
| Moxifloxacin | ≤0.015–0.064 | 1 | 1 | 23 (62) | 12 (32) | 2 (5) |
| Clarithromycin | 0.5–4 | >64 | >64 | 1 (3) | 0 (0) | 36 (97) |
| Minocycline | 0.06–4 | 4 | 4 | 4 (11) | 33 (89) | 0 (0) |
| Tigecycline (26) | 0.25–16 | 16 | >16 | – | – | – |
| **N. cyriacigeorgica** (27) |
| Amikacin | 0.125–4 | 0.5 | 2 | 27 (100) | 0 (0) | 0 (0) |
| Tobramycin | 0.125–1 | 0.25 | 0.5 | 27 (100) | 0 (0) | 0 (0) |
| Arbekacin (15) | 0.5–2 | 0.5 | 2 | – | – | – |
| Trimethoprim-sulfamethoxazole | 0.25/0.75–4/7.5 | 0.5 | 2/38 | 26 (96) | – | 1 (4) |
| Ceftriaxone | 1–4 | 16 | 256 | 1 (3) | 23 (62) | 5 (13) |
| Cefotaxime (15) | 2–32 | 4 | 16 | 11 (33) | 4 (12) | 35 (94) |
| Imipenem | 0.25–8 | 2 | 4 | 26 (96) | 1 (4) | 0 (0) |
| Meropenem (15) | 2–8 | 4 | 8 | – | – | – |
| Linezolid | 2–4 | 4 | 4 | 27 (100) | 0 (0) | 0 (0) |
| Ciprofloxacin | 4–32 | 16 | 32 | 0 (0) | 0 (0) | 27 (100) |
| Moxifloxacin | 1–8 | 4 | 8 | 1 (4) | 8 (30) | 18 (66) |
| Clarithromycin | 8–64 | >64 | >64 | 0 (0) | 0 (0) | 27 (100) |
| Minocycline | 2–8 | 2 | 4 | 0 (0) | 27 (100) | 0 (0) |
| Tigecycline (15) | 2–16 | 8 | 16 | – | – | – |
| **N. nova complex** (23) |
| Amikacin | 0.06–1 | 0.25 | 0.5 | 23 (100) | 0 (0) | 0 (0) |
| Tobramycin | 0.25–0.25 | 64 | 256 | 3 (13) | 1 (4) | 19 (83) |
| Arbekacin (13) | 0.125–0.5 | 0.25 | 0.5 | – | – | – |
| Trimethoprim-sulfamethoxazole | 0.125–0.25 | 1/19 | 2/38 | 23 (100) | 0 (0) | 0 (0) |
| Ceftriaxone | ≤0.016–0.064 | 8 | 16 | 18 (78) | 5 (22) | 0 (0) |
| Cefotaxime (13) | 4–32 | 8 | 16 | 8 (62) | 5 (38) | 0 (0) |
| Imipenem | ≤0.015–0.25 | 0.125 | 0.25 | 23 (100) | 0 (0) | 0 (0) |
| Meropenem (13) | 0.125–1 | 0.5 | 1 | – | – | – |
| Linezolid | ≤0.25–4 | 2 | 4 | 23 (100) | 0 (0) | 0 (0) |
| Ciprofloxacin | 4–32 | 16 | 32 | 0 (0) | 0 (0) | 23 (100) |
| Moxifloxacin | 2–4 | 2 | 4 | 0 (0) | 12 (52) | 11 (48) |
| Clarithromycin | 0.03–0.25 | 0.25 | 0.5 | 22 (96) | 0 (0) | 1 (4) |
| Minocycline | ≤0.5–8 | 4 | 8 | 1 (4) | 19 (83) | 3 (13) |
| Tigecycline (13) | 4–16 | 16 | >16 | – | – | – |
| **N. abscessus complex** (18) |
| Amikacin | 0.125–0.25 | 0.25 | 0.25 | 18 (100) | 0 (0) | 0 (0) |
| Tobramycin | 0.25–1 | 0.5 | 1 | 18 (100) | 0 (0) | 0 (0) |
| Arbekacin (15) | 0.03–0.125 | 0.06 | 0.125 | – | – | – |
| Trimethoprim-sulfamethoxazole | 0.25/0.75–2/3.75 | 0.5/1.9 | 1/19 | 18 (100) | 0 (0) | 0 (0) |
| Ceftriaxone | 0.5–16 | 2 | 16 | 16 (89) | 2 (11) | 3 (17) |
| Cefotaxime (15) | 0.5–16 | 4 | 8 | 14 (93) | 1 (7) | 0 (0) |
| Imipenem | 0.25–32 | 2 | 32 | 13 (72) | 2 (11) | 3 (17) |
| Meropenem (15) | 0.5–4 | 1 | 4 | – | – | – |
| Linezolid | 0.25–4 | 2 | 4 | 18 (100) | 0 (0) | 0 (0) |

Continued
| Bacterium (no of isolates tested) and antimicrobial agent | MIC (μg/ml) | Susceptibility (%)a |
|----------------------------------------------------------|-------------|---------------------|
|                                                         | Range       | 50%     | 90%     | S       | I       | R       |
| Ciprofloxacin                                           | 0.5–> 32    | 8       | > 32    | 4 (22)  | 1 (6)   | 13 (72) |
| Moxifloxacin                                            | 0.125–> 32  | 2       | > 32    | 3 (17)  | 6 (33)  | 9 (50)  |
| Clarithromycin                                          | 0.25–> 64   | 16      | > 64    | 4 (22)  | 2 (11)  | 12 (67) |
| Minocycline                                             | ≤ 0.5–4     | 1       | 4       | 12 (67) | 6 (33)  | 0 (0)   |
| Tigecycline (15)                                        | 0.5–> 16    | 1       | > 16    | –       | –       | –       |
| N. brasiliensis (14)                                    |             |         |         |         |         |         |
| Amikacin                                               | 0.25–4      | 2       | 4       | 14 (100)| 0 (0)   | 0 (0)   |
| Tobramycin                                              | 0.125–0.5   | 0.25    | 0.25    | 14 (100)| 0 (0)   | 0 (0)   |
| Arbekacin (10)                                          | 0.5–1       | 0.5     | 1       | –       | –       | –       |
| Trimethoprim-sulfamethoxazole                           | 0.25/4.75–1/19 | 0.5/9.5 | 5/9.5   | 14 (100)| 0 (0)   | 0 (0)   |
| Ceftriaxone                                             | 2–> 256     | 64      | > 256   | 3 (21)  | 3 (21)  | 8 (57)  |
| Cefotaxime (10)                                         | 16–> 256    | > 256   | > 256   | 0 (0)   | 2 (20)  | 8 (80)  |
| Imipenem                                                | 1–> 32      | > 32    | > 32    | 2 (14)  | 0 (0)   | 12 (86) |
| Meropenem (10)                                          | 4–8         | 8       | 8       | –       | –       | –       |
| Linzolid                                                | 4–8         | 4       | 8       | 14 (100)| 0 (0)   | 0 (0)   |
| Ciprofloxacin                                           | 2–8         | 8       | 8       | 0 (0)   | 0 (0)   | 14 (100)|
| Moxifloxacin                                            | 0.5–2       | 1       | 2       | 11 (79)| 2 (14)  | 5 (57)  |
| Clarithromycin                                          | 8–> 64      | > 64    | > 64    | 0 (0)   | 0 (0)   | 14 (100)|
| Minocycline                                             | 1–4         | 2       | 4       | 2 (14)  | 12 (86)| 0 (0)   |
| Tigecycline (10)                                        | 1–4         | 1       | 2       | –       | –       | –       |
| N. otitidiscaviarum (11)                                |             |         |         |         |         |         |
| Amikacin                                               | 0.5–2       | 1       | 2       | 11 (100)| 0 (0)   | 0 (0)   |
| Tobramycin                                              | 1–64        | 4       | 16      | 6 (55)  | 3 (27)  | 2 (18)  |
| Arbekacin (6)                                           | 0.125–0.25  | 0.125   | 0.25    | –       | –       | –       |
| Trimethoprim-sulfamethoxazole                           | 0.5/9.5–4/76| 1/19    | 4/76    | 8 (73)  | –       | 3 (27)  |
| Ceftriaxone                                             | 128–> 256   | > 256   | > 256   | 0 (0)   | 0 (0)   | 11 (100)|
| Cefotaxime (6)                                          | > 256       | > 256   | > 256   | 0 (0)   | 0 (0)   | 6 (100) |
| Imipenem                                                | 8–> 32      | > 32    | > 32    | 2 (14)  | 0 (0)   | 11 (100)|
| Meropenem (6)                                           | 8–> 32      | 16      | > 32    | –       | –       | –       |
| Linzolid                                                | 1–8         | 4       | 4       | 11 (100)| 0 (0)   | 0 (0)   |
| Ciprofloxacin                                           | 2–32        | 4       | 16      | 0 (0)   | 3 (27)  | 8 (73)  |
| Moxifloxacin                                            | 1–8         | 2       | 8       | 2 (18)  | 4 (36)  | 5 (45)  |
| Clarithromycin                                          | > 64        | > 64    | > 64    | 0 (0)   | 0 (0)   | 11 (100)|
| Minocycline                                             | 0.125–2     | 0.5     | 1       | 10 (91)| 1 (9)   | 0 (0)   |
| Tigecycline (6)                                         | 0.5–2       | 1       | 2       | –       | –       | –       |
| N. transvalensis complex* (6)                           |             |         |         |         |         |         |
| Amikacin                                               | 16–> 256    | 128     | > 256   | 0 (0)   | 0 (0)   | 6 (100) |
| Tobramycin                                              | > 256       | > 256   | > 256   | 0 (0)   | 0 (0)   | 6 (100) |
| Arbekacin (6)                                           | 4–16        | 4       | 16      | –       | –       | –       |
| Trimethoprim-sulfamethoxazole                           | 0.25/4.75–8/152| 1/19  | 8/152   | 4 (67)  | –       | 2 (33)  |
| Ceftriaxone                                             | 0.5–16      | 1       | 16      | 5 (83)  | 1 (17)  | 0 (0)   |
| Cefotaxime                                              | 0.5–32      | 2       | 32      | 5 (83)  | 1 (17)  | 0 (0)   |
| Imipenem                                                | 0.5–> 32    | 4       | > 32    | 3 (50)  | 1 (17)  | 2 (33)  |
| Meropenem                                               | 0.125–8     | 0.5     | 8       | –       | –       | –       |
| Linzolid                                                | 1–4         | 2       | 4       | 6 (100) | 0 (0)   | 0 (0)   |
| Ciprofloxacin                                           | 0.5–4       | 1       | 4       | 5 (83)  | 0 (0)   | 1 (17)  |
| Moxifloxacin                                            | 0.125–32    | 0.25    | 32      | 5 (83)  | 0 (0)   | 1 (17)  |
| Clarithromycin                                          | 2–64        | 8       | 64      | 1 (17)  | 0 (0)   | 5 (83)  |
| Minocycline                                             | 1–4         | 2       | 4       | 1 (17)  | 5 (83)  | 0 (0)   |
| Tigecycline                                             | 4–> 16      | 16      | > 16    | –       | –       | –       |

**Table 2.** Activities of antimicrobial agents against the 7 most frequently isolated *Nocardia* species/complexes.

aS, susceptible; I, intermediate; R, resistant.  
b*N. farcinica* and *Nocardia kroppenstedtii* were included in the *N. farcinica* complex.  
c*N. nova*, *N. elegans*, and *N. aobensis* were included in the *N. nova* complex.  
d*N. abscessus*, *N. asiatica*, *N. beijingensis*, and *N. arthritidis* were included in the *N. abscessus* complex.  
e*N. wallacei* and *N. transvalensis* were included in the *N. transvalensis* complex.
For the 100 Nocardia isolates, the MIC_{50} and MIC_{90} values of tigecycline were 8 and > 16 μg/ml, respectively. These values for N. brasiliensis and N. otitidiscaviarum, 1 and 2 μg/ml, respectively, were lower than those for the other frequently isolated Nocardia species. The MIC_{50} and MIC_{90} values of minocycline for those 100 Nocardia isolates were 4 and 4 μg/ml, respectively.

Table 3. Activities of antimicrobial agents against 10 clinical isolates of uncommon Nocardia species. a The MIC range is shown, with the percentage of susceptible isolates or susceptibility category (S, susceptible; I, intermediate; R, resistant) in parentheses. The number of isolates for each species is shown in parentheses. b2/3 isolates were identified as N. testacea/N. sienata, and 1/3 isolates was identified as N. testacea/N. flavorosea/N. sienata/N. rhamnosiphila by full-length 16S rRNA gene sequencing.

Table 4. Results of disk diffusion testing with a 250-μg sulfisoxazole disk and re-analysis of broth microdilution method against 21 TMP-SMX-resistant isolates. a A zone ≥ 35 mm indicates susceptibility, zones between 16 and 34 mm are not interpretable, and a zone ≤ 15 mm indicates resistance.
The cumulative percentages of the 100 *Nocardia* isolates inhibited by each concentration of arbekacin, amikacin and tobramycin are shown in Fig. 2. The MIC\(_{50}\) and MIC\(_{90}\) values of arbekacin, amikacin and tobramycin were 0.25 and 1, 1 and 4, and 4 and 128 μg/ml, respectively. Arbekacin showed low MIC values (4–16 μg/ml) even against *N. transvalensis* complex, which included high-level amikacin-resistant isolates (> 256 μg/ml).

**Detection of plasmid-mediated TMP-SMX-resistant genes.** None of the five TMP-SMX-resistant isolates or the remaining 16 isolates (TMP-SMX ≥ 4/76 μg/ml) carried either plasmid-mediated sulfonamide-resistant genes (*sul1*, *sul2*) or trimethoprim-resistant gene (*dfrA*).

**Discussion**

There is limited information about the distribution and antimicrobial susceptibility of various *Nocardia* species in Japan. In the present study, *N. farcinica* complex (25%) was the most common species, followed by *N. cyriacigeorgica* (18%), *N. brasiliensis* (9%), *N. nova* (8%), and *N. otitidiscaviarum* (7%), according to full-length 16S rRNA gene sequence identification. When using the complex criteria for MALDI-TOF MS identification\(^1\), *N. farcinica* complex (25%) remained the most predominant, but the next most dominant species were *N. cyriacigeorgica* and *N. nova* complex (18.3% each), followed by the *N. abscessus* complex (12%), and *N. brasiliensis* (9%). These epidemiological data, taken together with the antimicrobial susceptibility profiles of different species/complexes, may contribute to accurate empirical treatment decisions.

The current study demonstrates that MALDI-TOF MS is useful for rapidly and accurately providing species/complex identification of *Nocardia* species. The direct spotting and standard bacterial extraction methods developed for MALDI-TOF MS are suboptimal for *Nocardia* species, due to the hardness and composition of the cell wall\(^7\). Previous studies have stressed the need for enhanced sample preparation methods to sufficiently identify *Nocardia* species\(^9\)\(^{\text{18-21}}\). Khot et al. reported that the age of *Nocardia* cultures plays an important role in the success of MALDI-TOF MS identification, and recommended to use a colony at an early stage of growth\(^8\). Their method correctly identified 82.8% (72/87) to the species/complex level and 11.5% (10/87) to the genus level if the cut-off for species-level identification was lowered from a score of ≥ 2.00 to ≥ 1.90. The results of the current study indicate that our method is more reliable than Khot's method, despite the strict threshold value for species-level identification being used. The point of the method used in the present study was to use a colony at an early stage of growth (18–48 h cultivation), and to use a considerably augmented reference spectrum database created with well-characterized strains cultured in the same condition (18–48 h cultivation).

Our results indicate that TMP-SMX still has a good activity against *Nocardia* species isolated in Japan. TMP-SMX-resistant isolates were found among *N. otitidiscaviarum*, *N. cyriacigeorgica* and *N. mexicana*. The mechanism of resistance to TMP-SMX is being studied mainly in clinically important bacteria such as *Escherichia coli* and *Salmonella* species. It has been reported that acquisition of plasmid-mediated resistance genes (*sul* and *dfr*) and chromosomal gene mutations in the *dhisps* and *dhfr* genes coding for the target enzymes dihydropteroate synthase (DHFPS) and dihydrofolate reductase (DHFR), respectively, is the major resistance mechanisms\(^22\)\(^{\text{23}}\) in such bacteria. To the best of our knowledge, the mechanism of TMP-SMX resistance in *Nocardia* species has not yet been clarified, although a recent study reported that the acquisition of plasmid-mediated resistance genes is
involved in high resistance as in general bacteria. Valdezate et al. investigated 76 high-level TMP-SMX-resistant Nocardia isolates (≥ 32/608 μg/ml) isolated in Spain between 2007 and 2013, and found that these isolates possessed either one or multiple plasmid-mediated sulfonamide- and/or trimethoprim-resistant genes (sul1, 93.4%; sul2, 78.3%; and dfrA, 14.7%)32. In the present study, we could not find such a strain in the five TMP-SMX-resistant isolates. The MICs of these TMP-SMX-resistant isolates ranged from 4/76 to 8/152 μg/ml, and there were no high-level TMP-SMX-resistant Nocardia isolates. These results suggest that low level resistance around the MIC breakpoints may occur with different resistant mechanisms. Mehta et al. conducted an in vitro experimental evolution study to adapt susceptible clinical isolates of N. cyriacigeorgica and N. nova to the treatment of choice, TMP-SMX. They found that chromosomal gene mutations were seen within genes encoding DHFR, DHPS and a homolog (folP2) of the gene encoding DHPS in experimental de novo resistant strains26. While their study did not include sequence data of clinically TMP-SMX-resistant Nocardia strains, they suggested that chromosomal gene mutations may be implicated in low-level TMP-SMX resistance identical to that of other bacterial species, such as E. coli27.

On the other hand, it is known that TMP-SMX therapy is strongly associated with the emergence of thymidine-dependent small colony variants (SCVs) in Staphylococcus species29. Underlying mutations have been identified for thymidine-dependent SCVs in S. aureus, and mutations of the thyA gene have been shown to be responsible for the SCV phenotype30. The SCVs have also been found in some clinically important bacteria such as Stenotrophomonas maltophilia, P. aeruginosa, E. coli, Salmonella species, and Enterococcus species30–32. The SCV phenotype is characterized by small colony size, slow growth on agar media compared to wild-type isolates, and the inability to generate in vitro susceptibility results under standard conditions, as defined by CLSI30. Unfortunately, to date there have been no reports on SCVs in Nocardia species. Mehta et al. reported that a point mutation was observed at 16 bp upstream of thyA, which is an operon with the DHFR gene (folA), in experimental de novo TMP-SMX-resistant Nocardia strains, although they did not investigate the relationship between the mutation and SCV phenotype26. Nocardia infections are not uncommon in immunosuppressed patients receiving TMP-SMX for prophylaxis33; therefore, the existence of SCVs in Nocardia species cannot be denied. Further, TMP-SMX is frequently used not only for prophylaxis, but also for long-term treatment over 6 months1, so it is necessary to elucidate the resistance mechanisms, including chromosomal gene mutations and SCVs, and to develop an accurate detection method for TMP-SMX-resistant strains.

Tigecycline is the first in a new class of antimicrobials, a member of the glycyclines, and is an analogue of minocycline with additional properties that negate most mechanisms, mediating resistance to tetracyclines33. In vitro testing has revealed that tigecycline is active against Gram-positive cocci, including Enterococcus species, S. aureus and Streptococcus pneumoniae, and many species of multi-drug-resistant Gram-negative bacteria33. Lai et al. investigated 151 clinical isolates of Nocardia species, and reported that tigecycline had a low MIC (1 μg/ml), and that MIC values were ≤ 8 μg/ml against all of the tested isolates, suggesting the potential clinical applicability of tigecycline for the treatment of nocardiosis34. In the present study, tigecycline had a low MIC distribution only for N. brasilienis, N. otitidisaviarum and some clinically unusual Nocardia species. Some researchers have reported that N. farcinica complex, N. nova complex and N. transvalensis complex isolates were less susceptible to tigecycline than N. abscessus, N. brasilienis, or N. otitidisaviarum35–37. Further studies are needed to demonstrate the clinical role of tigecycline in the management of nocardiosis.

To our knowledge, the present study is the first to have evaluated the activity of arbekacin against a diverse range of Nocardia species. Arbekacin is a broad-spectrum aminoglycoside licensed for systemic use in Japan and Korea, where it is usually used to treat methicillin-resistant S. aureus infections38–39. Matsumoto et al. reported that arbekacin is stable against aminoglycoside-inactivating enzymes such as (3′) aminoglycoside-phosphotransferase, (4′) aminoglycoside-adenyltransferase (AAD), or AAD (2′) and has a weak affinity for (6′-IV) aminoglycoside-acetyltransferase40,41. Therefore, arbekacin has antimicrobial activity against Gram-positive and -negative pathogens, including strains resistant to gentamicin, tobramycin, and amikacin40,42. In this study, arbekacin was four-fold more active than amikacin, and showed low MIC values even against N. transvalensis complex, which is reported to be resistant to all aminoglycosides43. These results indicate that arbekacin has a good potential to be a concomitant antibiotic for empirical therapy or therapy for serious nocardiosis infections.

In conclusion, the current study demonstrated that MALDI-TOF MS is a quick, easy and reliable method for the species/complex identification of Nocardia species. Accurate identification by MALDI-TOF MS and antimicrobial susceptibility profiles together can help earlier implementation of appropriate antimicrobial treatment and improvement of patient prognosis.

Received: 23 December 2020; Accepted: 2 August 2021
Published online: 18 August 2021

References
1. Wilson, J. W. Nocardiosis: Updates and clinical overview. Mayo Clin. Proc. 87, 403–407 (2012).
2. Hemmerbach-Miller, M., Stout, J. E., Woodworth, M. H., Cox, G. M. & Saullo, J. L. Nocardia infections in the transplanted host. Transpl. Infect. Dis. 20, e12902 (2018).
3. Margalit, I. et al. How do I manage nocardiosis? Clin. Microbiol. Infect. 27, 550–558 (2021).
4. Convillé, P. S. et al. Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species. J. Clin. Microbiol. 50, 1270–1280 (2012).
5. Brown-Elliott, B. A., Brown, J. M., Convillé, P. S. & Wallace, R. J. Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin. Microbiol. Rev. 19, 259–282 (2006).
6. Convillé, P. S., Brown-Elliott, B. A. & Witebsky, F. G. Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, and other aerobic actinomycetes. In Manual of clinical microbiology (eds Carroll, K. C. et al.) 525–557 (American Society for Microbiology, 2019).
7. Conville, P. S.
8. Conville, P. S., Brown-Elliott, B. A. & Witebsky, F. G.
9. Hemmerbach-Miller, M., Stout, J. E., Woodworth, M. H., Cox, G. M. & Saullo, J. L.
The authors thank microbiology laboratories, which provided the clinical isolates.
Author contributions
M.T., N.O. and A.U. designed research; M.T., D.T., K.O. and K.S. conducted review and editing; M.T., M.I., D.T., M.H., Y.T. and H.S. provided the laboratory tests, data analysis, and resources; and M.T. and K.S. wrote the paper.

Funding
This work was supported by grants from the Kurozumi Medical Foundation and Charitable Trust Laboratory Medicine Research Foundation of Japan.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-95870-2.

Correspondence and requests for materials should be addressed to M.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021